NBIX or NBY or OGEN
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NBIX’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 0 green FA rating(s), and OGEN’s FA Score reflects 0 green FA rating(s).
- NBIX’s FA Score: 0 green, 5 red.
- NBY’s FA Score: 0 green, 5 red.
- OGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NBIX’s TA Score shows that 6 TA indicator(s) are bullish while NBY’s TA Score has 5 bullish TA indicator(s), and OGEN’s TA Score reflects 5 bullish TA indicator(s).
- NBIX’s TA Score: 6 bullish, 4 bearish.
- NBY’s TA Score: 5 bullish, 3 bearish.
- OGEN’s TA Score: 5 bullish, 3 bearish.
Price Growth
NBIX (@Pharmaceuticals: Other) experienced а +5.50% price change this week, while NBY (@Biotechnology) price change was -3.85% , and OGEN (@Biotechnology) price fluctuated -13.49% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.06%. For the same industry, the average monthly price growth was +12.42%, and the average quarterly price growth was +15.65%.
The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.
Reported Earning Dates
NBIX is expected to report earnings on Aug 05, 2025.
NBY is expected to report earnings on Apr 02, 2025.
OGEN is expected to report earnings on Mar 14, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-0.06% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Biotechnology (-6.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| NBIX | NBY | OGEN | |
| Capitalization | 13.7B | 3.28M | 3.62M |
| EBITDA | 358M | -6.52M | -19.94M |
| Gain YTD | -15.231 | -6.156 | -54.346 |
| P/E Ratio | 57.20 | N/A | N/A |
| Revenue | 1.89B | 13.8M | 0 |
| Total Cash | 1.03B | 776K | 3.14M |
| Total Debt | 428M | 1.26M | 519K |
NBIX | NBY | OGEN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 54 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 41 Fair valued | 48 Fair valued | |
PROFIT vs RISK RATING 1..100 | 71 | 100 | 100 | |
SMR RATING 1..100 | 56 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 49 | 62 | 92 | |
P/E GROWTH RATING 1..100 | 44 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 85 | 50 | 35 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NBY's Valuation (41) in the Biotechnology industry is in the same range as OGEN (48) and is in the same range as NBIX (72). This means that NBY's stock grew similarly to OGEN’s and similarly to NBIX’s over the last 12 months.
NBIX's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as NBY (100) and is in the same range as OGEN (100). This means that NBIX's stock grew similarly to NBY’s and similarly to OGEN’s over the last 12 months.
NBIX's SMR Rating (56) in the Biotechnology industry is somewhat better than the same rating for NBY (98) and is somewhat better than the same rating for OGEN (99). This means that NBIX's stock grew somewhat faster than NBY’s and somewhat faster than OGEN’s over the last 12 months.
NBIX's Price Growth Rating (49) in the Biotechnology industry is in the same range as NBY (62) and is somewhat better than the same rating for OGEN (92). This means that NBIX's stock grew similarly to NBY’s and somewhat faster than OGEN’s over the last 12 months.
NBIX's P/E Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for NBY (100) and is somewhat better than the same rating for OGEN (100). This means that NBIX's stock grew somewhat faster than NBY’s and somewhat faster than OGEN’s over the last 12 months.
| NBIX | NBY | OGEN | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | 3 days ago 79% | 3 days ago 84% |
| Stochastic ODDS (%) | 3 days ago 57% | 3 days ago 90% | 3 days ago 86% |
| Momentum ODDS (%) | 3 days ago 73% | 3 days ago 90% | 3 days ago 86% |
| MACD ODDS (%) | 3 days ago 71% | 3 days ago 86% | 3 days ago 86% |
| TrendWeek ODDS (%) | 3 days ago 69% | 3 days ago 90% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 83% | 3 days ago 90% |
| Advances ODDS (%) | 5 days ago 71% | 14 days ago 82% | 17 days ago 82% |
| Declines ODDS (%) | 3 days ago 62% | 3 days ago 90% | 7 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 77% | 3 days ago 84% | 3 days ago 79% |
| Aroon ODDS (%) | 3 days ago 73% | 3 days ago 86% | 3 days ago 90% |
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| ANY.X | 3.521380 | 0.095430 | +2.79% |
| Anyswap cryptocurrency | |||
| RVN.X | 0.013479 | -0.000283 | -2.06% |
| Ravencoin cryptocurrency | |||
| QNT.X | 98.815740 | -2.845520 | -2.80% |
| Quant cryptocurrency | |||
| C98.X | 0.072924 | -0.002191 | -2.92% |
| Coin98 cryptocurrency | |||
| BAR.X | 1.904450 | -0.174480 | -8.39% |
| FC Barcelona Fan Token cryptocurrency | |||
NBIX and
Correlation & Price change
A.I.dvisor tells us that NBIX and LFCR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and LFCR's prices will move in lockstep.
| Ticker / NAME | Correlation To NBIX | 1D Price Change % | ||
|---|---|---|---|---|
| NBIX | 100% | -1.54% | ||
| LFCR - NBIX | 32% Poorly correlated | +1.16% | ||
| CGC - NBIX | 30% Poorly correlated | -2.24% | ||
| EOLS - NBIX | 30% Poorly correlated | -2.87% | ||
| TLRY - NBIX | 26% Poorly correlated | -3.28% | ||
| ACET - NBIX | 25% Poorly correlated | +27.49% | ||
More | ||||